A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

BACKGROUND: The combination of everolimus and the imidazoquinoline derivative, BEZ235 (dactolisib), a dual PI3K/mTOR inhibitor, demonstrated synergy in a preclinical model. OBJECTIVE: To establish clinical feasibility, a phase Ib dose-escalation trial investigating safety and pharmacokinetics of thi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Target Oncol
Glavni autori: Wise-Draper, Trisha M., Moorthy, Ganesh, Salkeni, Mohamad A., Karim, Nagla Abdel, Thomas, Hala Elnakat, Mercer, Carol A., Beg, M. Shalaan, O’Gara, Sue, Olowokure, Olugbenga, Fathallah, Hassana, Kozma, Sara C., Thomas, George, Rixe, Olivier, Desai, Pankaj, Morris, John C.
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2017
Teme:
Original Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5447332/
https://ncbi.nlm.nih.gov/pubmed/28357727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-017-0482-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items